Royal Bank of Canada
ARCT icon

Royal Bank of Canada’s Arcturus Therapeutics ARCT Stock Holding History

Royal Bank of Canada’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7K Sell
967
-776
-45% -$5.66K ﹤0.01% 6295
2025
Q4 		$10K Sell
1,743
-113,920
-98% -$1.23M ﹤0.01% 6396
2025
Q3 		$2.13M Sell
115,663
-12,536
-10% -$201K ﹤0.01% 3354
2025
Q2 		$1.67M Buy
128,199
+123,502
+2,629% +$1.46M ﹤0.01% 3452
2025
Q1 		$49K Buy
4,697
+3,262
+227% +$51.8K ﹤0.01% 5579
2024
Q4 		$24K Sell
1,435
-1,928
-57% -$36.3K ﹤0.01% 6032
2024
Q3 		$79K Sell
3,363
-288
-8% -$6.16K ﹤0.01% 5482
2024
Q2 		$88K Sell
3,651
-4,334
-54% -$131K ﹤0.01% 5339
2024
Q1 		$270K Sell
7,985
-3,658
-31% -$130K ﹤0.01% 4438
2023
Q4 		$366K Buy
11,643
+4,012
+53% +$95.4K ﹤0.01% 4547
2023
Q3 		$195K Buy
7,631
+2,558
+50% +$78.8K ﹤0.01% 4829
2023
Q2 		$145K Sell
5,073
-1,813
-26% -$49.4K ﹤0.01% 5020
2023
Q1 		$165K Buy
6,886
+905
+15% +$16.2K ﹤0.01% 4785
2022
Q4 		$101K Buy
5,981
+1,934
+48% +$33.7K ﹤0.01% 5436
2022
Q3 		$60K Sell
4,047
-173
-4% -$2.9K ﹤0.01% 5638
2022
Q2 		$67K Sell
4,220
-1,816
-30% -$35.6K ﹤0.01% 5576
2022
Q1 		$163K Sell
6,036
-3,953
-40% -$101K ﹤0.01% 5265
2021
Q4 		$370K Buy
9,989
+2,547
+34% +$104K ﹤0.01% 4740
2021
Q3 		$356K Buy
7,442
+5,447
+273% +$244K ﹤0.01% 4634
2021
Q2 		$68K Buy
1,995
+34
+2% +$1.15K ﹤0.01% 5828
2021
Q1 		$81K Sell
1,961
-1,115
-36% -$66.5K ﹤0.01% 5592
2020
Q4 		$133K Sell
3,076
-9,755
-76% -$661K ﹤0.01% 5149
2020
Q3 		$550K Buy
12,831
+5,701
+80% +$283K ﹤0.01% 3770
2020
Q2 		$334K Buy
7,130
+6,130
+613% +$211K ﹤0.01% 4083
2020
Q1 		$14K Buy
+1,000
New +$12.8K ﹤0.01% 5688
2019
Q4 		– Sell
-122
Closed -$1K – 6797
2019
Q3 		$1K Buy
+122
New +$1.32K ﹤0.01% 6396
2018
Q4 		– Sell
-17
Closed – – 6721
2018
Q3 		$0 Buy
+17
New +$142 ﹤0.01% 6696
2017
Q1 		– Hold
0
– – – 6591
2016
Q4 		– Hold
0
– – – 6617

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada's ARCT Position: Q1 2026 in Review

Royal Bank of Canada reduced its Arcturus Therapeutics (ARCT) stake by 45% in Q1 2026, selling an estimated $5.66K and leaving 967 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #6295.

Royal Bank of Canada first reported a position in ARCT in Q3 2018 and has held it in 27 quarters since. The position peaked at $2.13M in Q3 2025. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Royal Bank of Canada held 967 shares of Arcturus Therapeutics worth $7K as of Q1 2026.
  • Royal Bank of Canada sold 776 Arcturus Therapeutics shares in Q1 2026, an estimated $5.66K.
  • Arcturus Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6295 holding.
  • Royal Bank of Canada first reported a position in Arcturus Therapeutics in Q3 2018 and has held it in 27 quarters since.
  • Royal Bank of Canada's Arcturus Therapeutics position peaked at $2.13M in Q3 2025.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.